Amir Nashat is an entrepreneur partner and managing partner of Polaris Funds VI–IX at Polaris Partners. See sector focus and contact routes.
Amir Nashat is an entrepreneur partner and managing partner of Polaris Funds VI–IX at Polaris Partners, having joined the Boston-based venture firm in 2002 after earning his ScD in Chemical Engineering from MIT under Dr. Robert Langer. He focuses on investing in healthcare companies, particularly biotech firms built from MIT and academic platform technologies in immunology, oncology, and cell engineering. While specific check sizes and lead/follow behavior are not publicly detailed, he actively serves as CEO of Souffle Therapeutics and represents Polaris as a director at CAMP4 Therapeutics, Dewpoint Therapeutics, and Paratus Sciences. His notable portfolio includes Fate Therapeutics (NASDAQ: FATE), Freenome, Scholar Rock (NASDAQ: SRRK), and Syros Pharmaceuticals (NASDAQ: SYRS), many of which he previously led as CEO. Nashat was named to the Forbes Midas List of Top 100 Venture Capitalists in 2016 and holds extensive board experience across biotech and deep tech companies. He also serves on the Investment Advisory Committee for The Engine at MIT and helped launch the MIT Sandbox Innovation Fund as its active president, reflecting a distinctive commitment t
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Boston when building a target list.
Investors like Amir Nashat · Full investor directory · Investor access · Company funding database